Dianthus Therapeutics (DNTH) Competitors $34.46 -0.48 (-1.37%) Closing price 04:00 PM EasternExtended Trading$34.12 -0.34 (-0.99%) As of 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNTH vs. PTCT, MENS, ARWR, ACLX, PCVX, CRNX, PTGX, KYMR, MLTX, and AKROShould you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include PTC Therapeutics (PTCT), Jyong Biotech (MENS), Arrowhead Pharmaceuticals (ARWR), Arcellx (ACLX), Vaxcyte (PCVX), Crinetics Pharmaceuticals (CRNX), Protagonist Therapeutics (PTGX), Kymera Therapeutics (KYMR), MoonLake Immunotherapeutics (MLTX), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry. Dianthus Therapeutics vs. Its Competitors PTC Therapeutics Jyong Biotech Arrowhead Pharmaceuticals Arcellx Vaxcyte Crinetics Pharmaceuticals Protagonist Therapeutics Kymera Therapeutics MoonLake Immunotherapeutics Akero Therapeutics PTC Therapeutics (NASDAQ:PTCT) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends. Which has more risk & volatility, PTCT or DNTH? PTC Therapeutics has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Is PTCT or DNTH more profitable? PTC Therapeutics has a net margin of 35.65% compared to Dianthus Therapeutics' net margin of -2,364.56%. Dianthus Therapeutics' return on equity of -34.72% beat PTC Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PTC Therapeutics35.65% -106.31% 30.61% Dianthus Therapeutics -2,364.56%-34.72%-32.72% Which has preferable earnings & valuation, PTCT or DNTH? Dianthus Therapeutics has lower revenue, but higher earnings than PTC Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPTC Therapeutics$806.78M6.38-$363.30M$6.979.30Dianthus Therapeutics$6.24M177.77-$84.97M-$3.25-10.60 Do analysts prefer PTCT or DNTH? PTC Therapeutics presently has a consensus target price of $69.00, indicating a potential upside of 6.48%. Dianthus Therapeutics has a consensus target price of $61.57, indicating a potential upside of 78.68%. Given Dianthus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dianthus Therapeutics is more favorable than PTC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PTC Therapeutics 1 Sell rating(s) 6 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.50Dianthus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80 Do insiders & institutionals believe in PTCT or DNTH? 47.5% of Dianthus Therapeutics shares are held by institutional investors. 5.5% of PTC Therapeutics shares are held by company insiders. Comparatively, 16.6% of Dianthus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor PTCT or DNTH? In the previous week, Dianthus Therapeutics had 2 more articles in the media than PTC Therapeutics. MarketBeat recorded 6 mentions for Dianthus Therapeutics and 4 mentions for PTC Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.62 beat PTC Therapeutics' score of 0.40 indicating that Dianthus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dianthus Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryDianthus Therapeutics beats PTC Therapeutics on 10 of the 15 factors compared between the two stocks. Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNTH vs. The Competition Export to ExcelMetricDianthus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.11B$3.35B$6.10B$10.62BDividend YieldN/A2.28%5.64%4.69%P/E Ratio-10.6022.1685.6627.13Price / Sales177.77265.75527.82206.05Price / CashN/A46.3226.3031.10Price / Book2.899.9612.926.67Net Income-$84.97M-$52.42M$3.30B$276.23M7 Day Performance-12.87%5.95%4.80%3.31%1 Month Performance30.04%11.59%8.11%10.76%1 Year Performance23.07%25.01%75.85%33.58% Dianthus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNTHDianthus Therapeutics3.2428 of 5 stars$34.46-1.4%$61.57+78.7%+24.8%$1.11B$6.24M-10.6080PTCTPTC Therapeutics3.4621 of 5 stars$60.65+2.8%$69.00+13.8%+86.2%$4.69B$806.78M8.701,410MENSJyong BiotechN/A$50.00-16.3%N/AN/A$4.54BN/A0.0031ARWRArrowhead Pharmaceuticals3.9214 of 5 stars$33.78+3.0%$43.14+27.7%+91.9%$4.53B$572.98M-26.39400Insider TradeACLXArcellx2.1773 of 5 stars$79.11-0.8%$114.31+44.5%+8.7%$4.42B$56.98M-23.1380PCVXVaxcyte2.4717 of 5 stars$34.65+2.0%$106.25+206.6%-61.7%$4.41BN/A-8.43160Positive NewsCRNXCrinetics Pharmaceuticals3.9306 of 5 stars$43.51-5.2%$73.20+68.2%-23.1%$4.32B$1.04M-10.59210Insider TradePTGXProtagonist Therapeutics2.2518 of 5 stars$65.14-3.4%$68.36+4.9%+46.1%$4.19B$434.43M93.06120Positive NewsKYMRKymera Therapeutics1.9564 of 5 stars$58.50+4.0%$59.95+2.5%+34.5%$4.02B$47.07M-16.86170MLTXMoonLake Immunotherapeutics2.9826 of 5 stars$6.24-89.9%$57.00+813.5%-84.8%$3.98BN/A-2.242Analyst RevisionGap UpHigh Trading VolumeAKROAkero Therapeutics3.7355 of 5 stars$47.62-0.3%$81.14+70.4%+63.2%$3.82BN/A-23.8130Positive NewsAnalyst UpgradeInsider Trade Related Companies and Tools Related Companies PTC Therapeutics Alternatives Jyong Biotech Alternatives Arrowhead Pharmaceuticals Alternatives Arcellx Alternatives Vaxcyte Alternatives Crinetics Pharmaceuticals Alternatives Protagonist Therapeutics Alternatives Kymera Therapeutics Alternatives MoonLake Immunotherapeutics Alternatives Akero Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DNTH) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredWarren Buffett’s #1 AI Stock is Not Even on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A Millionaire With SEVEN Clicks? $1,000 in just seven stocks in 2004 could have turned into a million-dolla...The Oxford Club | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
